Biogen, Genentech amend deal on MS drug

Discuss Ocrelizumab, a monoclonal antibody treatment for MS.

Biogen, Genentech amend deal on MS drug

Postby MSUK » Thu Oct 21, 2010 11:45 pm


Biogen Idec Inc. and Genentech said Thursday they amended their development agreement on a potential multiple sclerosis treatment.
Genentech, a unit of Swiss drug developer Roche, will now have responsibility for the further development of ocrelizumab in multiple sclerosis and will fund all the costs going forward.

Biogen will receive tiered, double-digit royalties on U.S. sales that will approximate its current 30 percent interest in the compound........... Read More - ... ageid/1397
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Return to Ocrevus (Ocrelizumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service